Answers are grounded in this paper and cite their sources.
Randomized single-blind trial finds anterior and posterior turbinate botulinum toxin injections provide equivalent symptom relief in refractory chronic rhinitis, supporting a flexible approach.
Background Refractory chronic rhinitis often persists despite standard medical therapy. Botulinum toxin type A (BTX-A) injection into the inferior turbinates offers a minimally invasive alternative, but the influence of the injection site within the turbinate is unknown. This study compared the efficacy and safety of anterior versus posterior inferior turbinate BTX-A injections in refractory chronic rhinitis. Methods In this randomized, single-blinded clinical trial conducted from 2023 to 2025, 50 adults with refractory chronic rhinitis were randomized to receive 30 units of BTX-A injected submucosally under endoscopic guidance into either the anterior ( n = 25) or posterior ( n = 25) inferior turbinate bilaterally. The primary outcome was change in Sino-Nasal Outcome Test-22 score from baseline to 1 and 3 months post-injection. Secondary outcomes included rhinorrhea severity (0–5 Likert scale), nasal discharge on endoscopy, and adverse events. Data were analyzed using independent and paired t-tests in SPSS version 25. Results Groups were balanced at baseline (mean age 39.4–40.6 years, 48–56% female). Mean SNOT-22 scores decreased significantly from baseline (24.8 ± 4.8 anterior; 24.4 ± 4.7 posterior) to 1 month (10.5 ± 3.1 anterior; 9.8 ± 2.4 posterior) and remained stable at 3 months (10.4 ± 3.5 anterior; 10.9 ± 3.4 posterior), with no between-group differences ( P = 0.745, 0.393, 0.656, respectively). Within-group reductions were highly significant ( P < 0.001), representing ~ 58–60% improvement. Nasal discharge decreased from 100% at baseline to 28–36% at 1 month and 52–60% at 3 months, with similar rhinorrhea improvements and no inter-group differences (all P > 0.05). Conclusions Anterior and posterior inferior turbinate BTX-A injections provide equivalent, rapid, and sustained symptom relief in refractory chronic rhinitis with excellent safety. Injection site does not affect efficacy, supporting a flexible technique. Larger trials with extended follow-up are needed. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Mohebbi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: